Treatment of Metastatic Renal Cell Carcinoma

Richter, Igor; Dvořák, Josef

doi:10.14735/amko2018110

Cited by 9 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is similar to the global incidence of 337 000 cases with 143 000 deaths 5. The Czech Republic has the highest incidence of RCC worldwide 1. Some have suggested that arsenic exposure or higher rates of smoking and obesity (smoking increases the risk of RCC by 50% in male and 20% in female smokers, and 5 kg/m 2 increments in body mass index (BMI) increase the risk of RCC by 24% in men and 34% in women) are to blame, but surrounding countries such as Slovakia do not have a large enough difference in risk factors for this to be the case 6.…”

Section: Discussionsupporting

confidence: 74%

See 1 more Smart Citation

Robust response to nivolumab in patient with renal cell carcinoma inferior vena cava tumour thrombus

Berends¹,

Gourley²,

Kaushik³

2019

BMJ Case Rep

View full text Add to dashboard Cite

A 47-year-old previously healthy man presented with acute moderate flank pain. Evaluation revealed left renal cell carcinoma, with inferior vena cava tumour thrombus invasion. Patient had no significant history or risk factors to pre-dispose him to genitourinary cancers. Surgery was deemed to not be appropriate due to distant metastases, but patient received targeted molecular therapy and immunotherapy with striking regression of the thrombus.

show abstract

Section: Discussionsupporting

confidence: 74%

“…Renal cell carcinoma (RCC) is a common cancer, believed to make up 2%–3% of all cancers worldwide 12.…”

Section: Introductionmentioning

confidence: 99%

Robust response to nivolumab in patient with renal cell carcinoma inferior vena cava tumour thrombus

Berends¹,

Gourley²,

Kaushik³

2019

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…Renal cell carcinoma has a worse prognosis and easily develop metastatic disease, which are usually incurable, and the median survival of metastatic RCC patients is significantly worse . Currently, the treatments for RCC have evolved from conventional drugs to biologic targeting therapies, among which cytokines are the most crucial therapeutic targets . However, the existing therapies for RCC are not satisfactory owing to the low efficacy in suppressing disease activity as well as the adverse effects in patients.…”

Section: Discussionmentioning

confidence: 99%

“…29 Currently, the treatments for RCC have evolved from conventional drugs to biologic targeting therapies, among which cytokines are the most crucial therapeutic targets. 30,31 However, the existing therapies for RCC are not satisfactory owing to the low efficacy in suppressing disease activity as well as the adverse effects in patients. In this study, H1 nanoparticles with a low toxicity were applied in the delivery system of targeting therapeutic.…”

Section: Discussionmentioning

confidence: 99%

H1/pAIM2 nanoparticles exert anti‐tumour effects that is associated with the inflammasome activation in renal carcinoma

Chai

Liu

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a high metastasis tumour with less effective treatment available currently. Absent in melanoma 2 (AIM2) as a tumour suppressor might be used as a potential therapeutic target for RCC treatment. Here, we found that AIM2 expression was significantly decreased in RCC patient specimens and renal carcinoma cell lines (786‐O and OSRC‐2). To establish a safe and effective AIM2 gene delivery system, we formed the nanoparticles consisting of a folate grafted PEI600‐CyD (H1) nanoparticle‐mediated AIM2 gene (H1/pAIM2) as an effective delivery agent. Delivery of H1/pAIM2 in renal carcinoma cells could remarkably increase the expression of AIM2, and subsequently decrease cell proliferation, migration, and invasion as well as enhance cell apoptosis. In order to evaluate the therapeutic efficacy of AIM2 in vivo, H1/pAIM2 nanoparticles were injected intratumorally into 786‐O‐xenograft mice. Administration of H1/pAIM2 nanoparticles could inhibit the tumour growth as evidenced by reduced tumour volume and weight. Furthermore, Blockade of inflammasome activation triggered by H1/pAIM2 nanoparticles using inflammasome inhibitor YVAD‐CMK abrogated the anti‐tumoral activities of H1/AIM2. These results indicated the therapeutic effect of H1/pAIM2 nanoparticles was mainly attributable to its capability to enhance the inflammasome activation. H1/AIM2 nanoparticles might act as an efficient therapeutic approach for RCC treatment.

show abstract

“…The distal metastases are usually found in the beginning of diagnosis or after primary tumor resection in a majority of patients with advanced renal carcinoma (3). Treatment of metastatic renal carcinoma is currently focused on antiangiogenic agents, cytokines, and mAbs (4). Although these agents have greatly improved patient survival in the development of advanced renal carcinoma treatment, the therapeutic effect, potentially serious side effects, and high drug costs are still not satisfactory (5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses

Chai

Shan

Wang

et al. 2019

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Renal carcinoma presents a rapid progression in patients with high metastasis with no effective therapeutic strategy. In this study, we designed a folate-grafted PEI600-CyD (H1) nanoparticle-mediated DNA vaccine containing an adjuvant of absent in melanoma 2 (AIM2) and a tumor-specific antigen of carbonic anhydrase IX (CAIX) for renal carcinoma therapy. Mice bearing subcutaneous human CAIX (hCAIX)-Renca tumor were intramuscularly immunized with H1-pAIM2/pCAIX, H1-pCAIX, H1-pAIM2, or Mock vaccine, respectively. The tumor growth of hCAIX-Renca was significantly inhibited in H1-pAIM2/pCAIX vaccine group compared with the control group. The vaccine activated CAIX-specific CD8 þ T-cell proliferation and CTL responses, and enhanced the induction of multi-functional CD8 þ T cells (expressing TNF-a, IL-2, and IFN-g).CD8 þ T-cell depletion resulted in the loss of anti-tumor activity of H1-pAIM2/pCAIX vaccine, suggesting that the efficacy of the vaccine was dependent on CD8 þ T-cell responses. Lung metastasis of renal carcinoma was also suppressed by H1-pAIM2/pCAIX vaccine treatment accompanied with the increased percentages of CAIX-specific multi-functional CD8 þ T cells in the spleen, tumor, and bronchoalveolar lavage as compared with H1-pCAIX vaccine. Similarly, the vaccine enhanced CAIX-specific CD8 þ T-cell proliferation and CTL responses. Therefore, these results indicated that H1-pAIM2/pCAIX vaccine exhibits the therapeutic efficacy of anti-renal carcinoma by enhancing tumor-specific multi-functional CD8 þ T-cell responses. This vaccine strategy could be a potential and promising approach for the therapy of primary solid or metastasis tumors.

show abstract

Treatment of Metastatic Renal Cell Carcinoma

Cited by 9 publications

References 21 publications

Robust response to nivolumab in patient with renal cell carcinoma inferior vena cava tumour thrombus

Robust response to nivolumab in patient with renal cell carcinoma inferior vena cava tumour thrombus

H1/pAIM2 nanoparticles exert anti‐tumour effects that is associated with the inflammasome activation in renal carcinoma

Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses

Contact Info

Product

Resources

About